291 related articles for article (PubMed ID: 22346545)
1. Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects.
Zhanel GG; Simor AE; Vercaigne L; Mandell L;
Can J Infect Dis; 1998 Jul; 9(4):215-28. PubMed ID: 22346545
[TBL] [Abstract][Full Text] [Related]
2. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
3. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
4. Carbapenems and monobactams: imipenem, meropenem, and aztreonam.
Hellinger WC; Brewer NS
Mayo Clin Proc; 1999 Apr; 74(4):420-34. PubMed ID: 10221472
[TBL] [Abstract][Full Text] [Related]
5. Meropenem: a review of its use in patients in intensive care.
Hurst M; Lamb HM
Drugs; 2000 Mar; 59(3):653-80. PubMed ID: 10776838
[TBL] [Abstract][Full Text] [Related]
6. Meropenem: a new carbapenem antimicrobial.
Pryka RD; Haig GM
Ann Pharmacother; 1994 Sep; 28(9):1045-54. PubMed ID: 7803882
[TBL] [Abstract][Full Text] [Related]
7. Comparative review of the carbapenems.
Zhanel GG; Wiebe R; Dilay L; Thomson K; Rubinstein E; Hoban DJ; Noreddin AM; Karlowsky JA
Drugs; 2007; 67(7):1027-52. PubMed ID: 17488146
[TBL] [Abstract][Full Text] [Related]
8. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.
Colardyn F; Faulkner KL
J Antimicrob Chemother; 1996 Sep; 38(3):523-37. PubMed ID: 8889726
[TBL] [Abstract][Full Text] [Related]
9. Meropenem: a review of its use in the treatment of serious bacterial infections.
Baldwin CM; Lyseng-Williamson KA; Keam SJ
Drugs; 2008; 68(6):803-38. PubMed ID: 18416587
[TBL] [Abstract][Full Text] [Related]
10. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.
Verwaest C;
Clin Microbiol Infect; 2000 Jun; 6(6):294-302. PubMed ID: 11168137
[TBL] [Abstract][Full Text] [Related]
11. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.
Wiseman LR; Wagstaff AJ; Brogden RN; Bryson HM
Drugs; 1995 Jul; 50(1):73-101. PubMed ID: 7588092
[TBL] [Abstract][Full Text] [Related]
12. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.
Geroulanos SJ
J Antimicrob Chemother; 1995 Jul; 36 Suppl A():191-205. PubMed ID: 8543495
[TBL] [Abstract][Full Text] [Related]
13. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F
Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862
[TBL] [Abstract][Full Text] [Related]
14. Meropenem: evaluation of a new generation carbapenem.
Blumer JL
Int J Antimicrob Agents; 1997 Mar; 8(2):73-92. PubMed ID: 18611786
[TBL] [Abstract][Full Text] [Related]
15. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
Kuo BI; Fung CP; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
[TBL] [Abstract][Full Text] [Related]
16. Comparative review of imipenem/cilastatin versus meropenem.
Salmon-Rousseau A; Martins C; Blot M; Buisson M; Mahy S; Chavanet P; Piroth L
Med Mal Infect; 2020 Jun; 50(4):316-322. PubMed ID: 32035719
[TBL] [Abstract][Full Text] [Related]
17. [Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study].
Tonelli F
Minerva Chir; 1997 Mar; 52(3):317-26. PubMed ID: 9148225
[TBL] [Abstract][Full Text] [Related]
18. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
Xiao YH; Hu YJ
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
[No Abstract] [Full Text] [Related]
19. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial.
Basoli A; Meli EZ; Mazzocchi P; Speranza V
Scand J Infect Dis; 1997; 29(5):503-8. PubMed ID: 9435041
[TBL] [Abstract][Full Text] [Related]
20. A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus.
Embil JM; Soto NE; Melnick DA
Clin Ther; 2006 Aug; 28(8):1164-1174. PubMed ID: 16982293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
